Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | SCN1A | P35498 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.51 |
| ▸ | SRC | P12931 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2502393 | 0.91 | ALDH1A1 (0.54) | HRH3ALDH1A1MAPK1CYP1A2CHRM2 | |
| SCHEMBL25345607 | 0.90 | EHMT2 (0.51) | HRH3ALDH1A1KCNH2KDM4E | |
| SCHEMBL4554146 | 0.88 | HRH3 (0.52) | HRH3ALDH1A1KDM4E | |
| SCHEMBL3067381 | 0.80 | HRH3 (0.54) | HRH3ALDH1A1MAPK1CYP1A2CHRM2 | |
| SCHEMBL30979868 | 0.80 | HRH3 (0.54) | HRH3ALDH1A1MAPK1CYP1A2CHRM2 | |
| SCHEMBL31061228 | 0.79 | ALDH1A1 (0.51) | HRH3ALDH1A1MAPK1CYP1A2CHRM2 | |
| SCHEMBL3351728 | 0.79 | ALDH1A1 (0.51) | HRH3ALDH1A1MAPK1CYP1A2CHRM2 | |
| SCHEMBL11274158 | 0.76 | ALDH1A1 (0.62) | HRH3ALDH1A1MAPK1CYP1A2CHRM2 | |
| SCHEMBL6652253 | 0.76 | DRD3 (0.58) | HRH3ALDH1A1MAPK1CYP1A2CHRM2 | |
| SCHEMBL29832175 | 0.76 | NCF1 (0.44) | CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104903450-A | Dosing and administration of oligonucleotide cancer therapies | PRONAI THERAPEUTICS INC | 2015-09-09 | — | — | CN | disclosed |
| CN-104884637-A | Methods of using biomarkers for the treatment of cancer by modulation of BCL2 expression | PRONAI THERAPEUTICS INC | 2015-09-02 | — | — | CN | disclosed |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | HRH3 586/4885ALDH1A1 730/4885MAPK1 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.